Callahan Advisors LLC grew its stake in Zoetis Inc (NYSE:ZTS) by 80.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,610 shares of the company’s stock after purchasing an additional 5,160 shares during the period. Callahan Advisors LLC’s holdings in Zoetis were worth $1,447,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently bought and sold shares of ZTS. Nuveen Asset Management LLC boosted its stake in shares of Zoetis by 40,874.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 7,078,826 shares of the company’s stock valued at $803,376,000 after purchasing an additional 7,061,550 shares in the last quarter. Stonehage Fleming Financial Services Holdings Ltd bought a new position in Zoetis in the 2nd quarter valued at approximately $133,113,000. Bank of New York Mellon Corp raised its holdings in Zoetis by 9.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,420,261 shares of the company’s stock valued at $501,654,000 after buying an additional 383,799 shares during the last quarter. Vanguard Group Inc. raised its holdings in Zoetis by 1.0% in the 2nd quarter. Vanguard Group Inc. now owns 36,765,577 shares of the company’s stock valued at $4,172,526,000 after buying an additional 346,167 shares during the last quarter. Finally, Natixis raised its holdings in Zoetis by 147.1% in the 2nd quarter. Natixis now owns 547,078 shares of the company’s stock valued at $62,088,000 after buying an additional 325,661 shares during the last quarter. Institutional investors own 90.05% of the company’s stock.
A number of brokerages recently issued reports on ZTS. Goldman Sachs Group began coverage on shares of Zoetis in a report on Monday, September 9th. They issued a “conviction-buy” rating and a $145.00 price objective for the company. Bank of America lowered shares of Zoetis from a “buy” rating to a “neutral” rating and raised their price objective for the company from $111.00 to $120.00 in a report on Monday, July 1st. They noted that the move was a valuation call. ValuEngine lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Morgan Stanley raised their price objective on shares of Zoetis from $100.00 to $136.00 and gave the company an “equal weight” rating in a report on Monday, September 30th. Finally, Credit Suisse Group set a $138.00 price target on shares of Zoetis and gave the stock a “buy” rating in a report on Friday, October 11th. Eight research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $123.69.
In other news, EVP Kristin C. Peck sold 11,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $123.22, for a total transaction of $1,417,030.00. Following the completion of the sale, the executive vice president now owns 48,877 shares of the company’s stock, valued at approximately $6,022,623.94. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Roxanne Lagano sold 4,463 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $125.99, for a total transaction of $562,293.37. Following the sale, the executive vice president now directly owns 33,190 shares of the company’s stock, valued at approximately $4,181,608.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,332 shares of company stock valued at $4,258,182. Insiders own 0.29% of the company’s stock.
Zoetis stock traded down $1.67 during mid-day trading on Monday, hitting $126.45. 1,640,931 shares of the stock were exchanged, compared to its average volume of 2,093,587. The company has a quick ratio of 2.87, a current ratio of 4.17 and a debt-to-equity ratio of 2.74. Zoetis Inc has a 12 month low of $78.90 and a 12 month high of $130.20. The firm’s fifty day simple moving average is $125.74 and its two-hundred day simple moving average is $114.41. The stock has a market capitalization of $61.35 billion, a price-to-earnings ratio of 40.40, a PEG ratio of 3.18 and a beta of 0.87.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The company’s revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.77 EPS. As a group, analysts forecast that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Tuesday, October 22nd will be given a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend is Monday, October 21st. Zoetis’s dividend payout ratio (DPR) is 21.09%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: What is the S&P 500 Index?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.